Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group Study
Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group Study
复制标题
DOI：
10.1200/jco.2001.19.5.1275
复制
发表时间：
2001-03-01
影响因子：
45.3
通讯作者：
Alvarez, RD
中科院分区：
文献类型：
--
作者：
Curtin, JP;Blessing, JA;Alvarez, RD
目的：在晚期非鳞状宫颈癌中启动紫杉醇的 II 期试验，以确定其在标准化疗失败的患者中的活性。患者和方法：符合条件的患者至少有一个可测量的病变。紫杉醇的起始剂量为 170 mg/m(2)（对于既往接受过盆腔放射治疗的患者为 135 mg/m(2)），24 小时连续静脉输注，每 3 周重复一次疗程。根据不良反应，允许剂量递增至 200 mg/m(2) 和降至 110 mg/m(2)。 结果：在本试验中，42 名可评估患者接受了治疗。 最初进入该研究，收到了 13 条回复； 4 名患者获得完全缓解，9 名患者获得部分缓解。总体回应率为 31%。主要的剂量限制性毒性是中性粒细胞减少症。结论：紫杉醇的反应率超过了使用其他单一药物治疗宫颈非鳞状癌的反应率。 J 临床肿瘤杂志 19：1275-1278。 (C) 2001 年美国临床肿瘤学会。
Purpose: A phase II trial of paclitaxel was initiated in advanced nonsquamous carcinoma of the cervix to determine its activity in patients who had failed standard chemotherapy.Patients and Methods: Eligible patients had at least one measurable lesion. The starting dose of paclitaxel was 170 mg/m(2) (135 mg/m(2) for patients with prior pelvic radiation) given as a 24-hour continuous intravenous infusion with courses repeated every 3 weeks, Dose escalation to 200 mg/m(2) and de-escalation to 110 mg/m(2) were allowed based on adverse effects.Results: In this trial, 42 assessable patients were initially entered onto the study, and 13 responses were seen; four patients had a complete response, and nine patients had a partial response. The overall response rate was 31%. The primary and dose-limiting toxicity was neutropenia.Conclusion: The response rate to paclitaxel exceeds the rates reported using other single agents in nonsquamous carcinoma of the cervix. J Clin Oncol 19:1275-1278. (C) 2001 by American Society of Clinical Oncology.